0001764046false00-000000000017640462026-10-062026-10-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
October 6, 2026
Date of Report (date of earliest event reported)
CLARIVATE PLC
(Exact name of registrant as specified in its charter)
| | | | | |
Jersey, Channel Islands |
| (State or other jurisdiction of incorporation or organization) |
| |
| 001-38911 |
| (Commission File Number) |
| |
| N/A |
| (I.R.S. Employer Identification No.) |
| |
70 St. Mary Axe |
| London | EC3A 8BE |
United Kingdom |
(Address of Principal Executive Offices) |
(44) 207-433-4000
Registrant's telephone number, including area code
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Ordinary Shares, no par value | CLVT | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01. Completion of Acquisition or Disposition of Assets.
On October 6, 2026, Clarivate Plc (“Clarivate”) completed the previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC (“Buyer”) pursuant to the Stock and Asset Purchase Agreement (the “Purchase Agreement”), dated as of July 3, 2026, between certain subsidiaries of Clarivate and Buyer (the “Transaction”).
At the closing of the Transaction (the “Closing”), Buyer paid to a wholly-owned subsidiary of Clarivate cash consideration of $500,000,000, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses as more fully set forth in the Purchase Agreement, and an affiliate of Buyer issued to a wholly-owned subsidiary of Clarivate an unsecured senior note in an aggregate principal amount of $75,000,000. In addition, deferred consideration of $25,000,000 is payable by Buyer to a wholly-owned subsidiary of Clarivate upon the latest of (x) 20 business days after the completion by a subsidiary of Clarivate of the transition services to be provided to the Buyer, (y) 20 business days after the receipt of the final payment for such services and (z) January 31, 2028 (but no later than January 31, 2028, in any case).
The foregoing description of the Purchase Agreement and the Transaction does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, a copy of which was filed as Exhibit 2.1 to Clarivate’s Current Report on Form 8-K filed with the SEC on July 6, 2026, and is incorporated by reference herein.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Upon the Closing and in connection with the Transaction, Henry Levy, Clarivate’s President, Life Sciences & Healthcare, terminated employment with a subsidiary of Clarivate. Pursuant to the terms of the retention agreement entered into between Mr. Levy and a subsidiary of Clarivate (the terms of which were previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2026), Clarivate entered into a separation agreement and release with Mr. Levy providing for the payments and benefits set forth in the retention agreement.
Item 8.01. Other Events.
On October 6, 2026, Clarivate issued a press release announcing the completion of the Transaction. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(b) Unaudited Pro Forma Condensed Consolidated Financial Information.
Clarivate expects to file the Unaudited Pro Forma Condensed Consolidated Balance Sheet of Clarivate as of June 30, 2026 and the Unaudited Pro Forma Condensed Consolidated Statements of Operations of Clarivate for the six months ended June 30, 2026 and for the years ended December 31, 2025, 2024 and 2023, giving effect to the Transaction, in a current report on Form 8-K no later than October 13, 2026, which is the fourth business day after the completion of the Transaction.
(d) Exhibits.
| | | | | |
| Exhibit No. | Description |
| 2.1* | Stock and Asset Purchase Agreement dated as of July 3, 2026 by and among Janus Buyer, LP, Camelot UK Bidco Limited, Clarivate Analytics (UK) Limited and Camelot U.S. Acquisition LLC (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Clarivate with the SEC on July 6, 2026). |
| 99.1 | Press Release issued by Clarivate Plc dated October 6, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Clarivate hereby agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| Date: October 6, 2026 | |
| CLARIVATE PLC |
| By: /s/ John Doulamis |
| Name: John Doulamis |
| Title: Senior Vice President, General Counsel |
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation
Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments
Proceeds strengthen balance sheet and enhance financial flexibility
London, U.K., October 6, 2026 – Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced the successful completion of the sale of its Life Sciences & Healthcare segment to Altaris, LLC (“Altaris”), advancing Clarivate’s transformation and simplifying its portfolio. The transaction for $600 million was previously announced on July 6, 2026.
With the completion of the transaction, Clarivate is now a more-focused subscription-first global provider of trusted proprietary data and authoritative content, AI-powered intelligence solutions, embedded workflow software, and tech-enabled services. The leading Academia & Government and Intellectual Property segments benefit from the deep subject matter expertise of Clarivate colleagues and shared infrastructure to serve customers at critical moments of innovation, research, learning, and intellectual property creation and protection. This helps organizations move from information overload to confident decision making.
Matti Shem Tov, Chief Executive Officer, Clarivate said: "This is an important milestone in Clarivate's transformation journey. The successful completion of this transaction further advances our Value Creation Plan by sharpening our focus, simplifying our portfolio, and strengthening our financial profile. We are now positioned as a more focused company centered on two market-leading segments with attractive recurring revenue characteristics, deep customer relationships, and significant opportunities to leverage AI-driven innovation."
"I want to thank our Life Sciences & Healthcare colleagues for their many contributions to Clarivate and wish them continued success as part of Altaris," Shem Tov continued. "We also thank our customers for their continued trust and partnership throughout this process."
As previously communicated, Clarivate intends to use the transaction proceeds to reduce debt and further strengthen its balance sheet, while enhancing strategic and financial flexibility. The transaction also supports the Company's efforts to improve revenue quality, expand profitability, and increase focus on long-term value creation.
Michael Easton, Chief Financial Officer, Clarivate said: "The completion of this transaction marks another meaningful step in executing our strategy. Our streamlined business model and stronger balance sheet position us well to invest in innovation, support our customers, and drive sustainable growth and shareholder value."
The Company will report its third quarter 2026 financial results on Tuesday, November 3, 2026, and will update its full year 2026 guidance to reflect the divestiture of the Life Sciences & Healthcare segment.
A more focused Clarivate
Following the divestiture, Clarivate's portfolio consists of:
Academia & Government
Providing trusted intelligence, workflow solutions, and services that help universities, research institutions, libraries, governments, and funders accelerate research, advance learning, and improve outcomes. Home to leading research, education and library solutions, including Web of Science, ProQuest, Alma and Vega.
Intellectual Property
Delivering leading patent, trademark, brand protection, and innovation intelligence solutions that help organizations create, protect, and commercialize intellectual property. Home to IPOne, Derwent, CompuMark, IPfolio and other leading IP solutions.
Together, these businesses are underpinned by proprietary content, workflow software, and expanding AI capabilities that help customers make faster, more informed decisions.
Forward-looking statements
This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the divestiture of our Life Sciences & Healthcare business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our Life Sciences & Healthcare business, any anticipated cost savings or other benefits as a result of the divestiture of our Life Sciences & Healthcare business, our financial guidance for the fiscal year 2026, key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan, our growth strategies and future business prospects, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government and Intellectual Property. For more information, please visit www.clarivate.com.
Investor Relations Contact
Mark Donohue, Head of Investor Relations
investor.relations@clarivate.com
Media Contact
Amy Bourke-Waite, Senior Director, Communications & Brand
newsroom@clarivate.com
